These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 27567847

  • 1. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.
    Klafki HW, Hafermann H, Bauer C, Haussmann U, Kraus I, Schuchhardt J, Muck S, Scherbaum N, Wiltfang J.
    J Alzheimers Dis; 2016 Sep 06; 54(2):691-705. PubMed ID: 27567847
    [Abstract] [Full Text] [Related]

  • 2. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H, Klafki HW, Bauer C, Schuchhardt J, Hüttenrauch M, Stazi M, Bouter C, Wirths O, Vogelgsang J, Wiltfang J.
    Alzheimers Res Ther; 2018 Dec 08; 10(1):121. PubMed ID: 30526652
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Fiorini M, Bongianni M, Benedetti MD, Monaco S, Zanusso G.
    J Alzheimers Dis; 2018 Dec 08; 66(1):219-227. PubMed ID: 30282368
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014 Dec 08; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 7. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
    Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Höjrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J.
    J Alzheimers Dis; 2013 Dec 08; 33(4):1021-32. PubMed ID: 23076076
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.
    Methods; 2012 Apr 08; 56(4):484-93. PubMed ID: 22503777
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.
    J Alzheimers Dis; 2016 Apr 08; 51(4):1069-83. PubMed ID: 26923009
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M, Almdahl IS, Wettergreen M, Nilsson LN, Fladby T.
    J Proteome Res; 2015 Nov 06; 14(11):4834-43. PubMed ID: 26452689
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM.
    J Alzheimers Dis; 2017 Nov 06; 55(2):813-822. PubMed ID: 27792012
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X, Shi H, Hou L, Zhong X, Chen X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chen J, Fang Y, He H, Ning Y.
    Eur J Neurol; 2015 May 06; 22(5):853-8. PubMed ID: 25707998
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.
    Schipke CG, Prokop S, Heppner FL, Heuser I, Peters O.
    Dement Geriatr Cogn Disord; 2011 May 06; 31(2):139-45. PubMed ID: 21304219
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.